Revolutionizing Hyperlipidaemia Treatment: Magnetic Nanoparticle-Based Delivery Systems.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Conventional systemic therapies for hyperlipidaemia face limitations in drug localisation and efficacy.
• Magnetic Drug Delivery Systems (MDDS) utilize magnetic nanoparticles (MNPs) for targeted drug delivery.
• MDDS aim to improve drug penetration and control at the site of action.

Purpose of the Study:

• To review the application of MDDS in hyperlipidaemia management.
• To explore advancements in MNP synthesis and design for enhanced drug delivery.
• To assess the translational potential and future directions of MDDS.

Main Methods:

• Review of literature on MDDS for hyperlipidaemia treatment.
• Discussion of Orlistat-enhanced magnetic systems for lipid-lowering therapy.
• Analysis of preclinical innovations including computational models, in vitro, and animal studies.

Main Results:

• MDDS demonstrate potential for targeted delivery of therapeutic agents, overcoming systemic therapy drawbacks.
• Advances in green chemistry, biomimetic coatings, and intelligent carriers are key to MNP development.
• Preclinical studies support the translational potential of MDDS for hyperlipidaemia.

Conclusions:

• MDDS represent a promising paradigm shift for targeted hyperlipidaemia treatment.
• Future directions include magnetoelectric nanoparticles, AI-driven magnetic field modulation, and wearable technology integration.
• Long-term stability, biocompatibility, and ethical considerations are crucial for clinical translation.